Aura Biosciences Q1 2024 net loss $19.7M; cash $202.9M funds into H2 2026

Aura Biosciences, Inc.

2024-Q1 EPS reported -$0.40

Net loss of $19.7M for Q1 2024 vs $17.5M in Q1 2023; R&D spend $17.1M (up from $14.4M).
Cash and marketable securities $202.9M as of March 31, 2024; expected to fund operations into H2 2026.
Phase 3 CoMpass trial for small choroidal melanoma enrolling globally; target ~100 patients.
Phase 1 bladder cancer trial enrolling; early data expected mid-2024; Fast Track designation from FDA.
Appointed Conor Kilroy as General Counsel and Secretary.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aura Biosciences, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Aura Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056252

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.